Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 2, 2010, Pages

  Johnson, Ali C M ^a   Becker, Kirsten ^a   Zager, Richard A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Fe gluconate; Fe sucrose; Ferumoxytol; Heme oxygenase 1

Indexed keywords

ENDOTOXIN; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; FERUMOXYTOL; GLYCEROL; HEME OXYGENASE 1; IRON DERIVATIVE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; ENDOTOXEMIA; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; UREMIA;

EID: 77955456688     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00248.2010     Document Type: Article

References (45)

1. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72: 638-642, 2007.
2. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
3. Burns DL, Pomposelli JJ. Toxicity of parenteral iron dextran therapy. Kidney Int 69: S119-S124, 1999.
4. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19: 1571-1575, 2004.
5. Corti MC, Gaziano M, Hennekens CH. Iron status, and risk of cardiovascular disease. Ann Epidemiol 7: 62-8, 1997.
6. Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin Pharmacother 10: 2563-2568, 2009.
7. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. Kidney Int 15: S93-S98, 2004.
8. Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis 52: 395-399, 2008.
9. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease, and anemia. N Engl J Med 355: 2071-2084, 2006. (Pubitemid 44749316)
10. Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR angiography of aortic stent-graft endoleak. Am J Roentgenol 182: 1181-1186, 2004.
11. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health, and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 4: 57-61, 2009.
12. Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med 15 31: 542-547, 2001.
13. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-analysis Investigator Group: accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis, and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54: 1012-1024, 2009.
14. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731, 1980.
15. Hsu CY, McCulloch CE, Curhan GC. Iron status, and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783-2786, 2002.
16. Iwata M, Herrington J, Zager RA. Protein synthesis inhibition induces cytoresistance in cultured human proximal tubular (HK-2) cells. Am J Physiol Renal Fluid Electrolyte Physiol 268: F1154-F1163, 1995.
17. Iwata M, Zager RA. Myoglobin inhibits proliferation of cultured human proximal tubular (HK-2) cells. Kidney Int 50: 796-804, 1996. (Pubitemid 26302667)
18. Jacobs P, Lewis J, Frigio T. Bleomycin detectable iron, and percent transferrin saturation in the serum of patients receiving either ferumoxytol, iron gluconate, or iron sucrose (Abstract). J Am Soc Nephrol 15: 546A, 2004.
19. Kanakiriya SK, Croatt AJ, Haggard JJ, Ingelfinger JR, Tang SS, Alam J, Nath KA. Heme: a novel inducer of MCP-1 through HO-dependent, and HO-independent mechanisms. Am J Physiol Renal Physiol 284: F546-F554, 2003.
20. Lewis J, Jacobs P, Frigio T. Comparison of free iron in ferumoxytol with other iron therapeutics (Abstract). J Am Soc Nephrol 14: 771A, 2003.
21. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85: 311-312, 2010.
22. Lu H, Daugherty A. Atherosclerosis: cell biology and lipoproteins . Curr Opin Lipidol 20: 528-529, 2009.
23. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003.
24. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophoreiron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115: 610-621, 2005.
25. Mosmann T. Rapid colorimetric assay for cellular growth, and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983. (Pubitemid 14203433)
26. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, Rosenberg ME. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90: 267-270, 1992.
27. Nath KA, Croatt AJ, Haggard JJ, Grande JP. Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int 57: 2423-2433, 2000.
28. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes, and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009.
29. Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 459: 218-222, 1999.
30. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4: 386-393, 2009.
31. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45: 48-57, 1994.
32. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18: 407-413, 2007. (Pubitemid 46193306)
33. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS, Agarwal A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 278: F726-F736, 2000. (Pubitemid 30351074)
34. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006. (Pubitemid 44749317)
35. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: 1599-605, 2008.
36. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M. The safety, and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 68: 1801-1807, 2005.
37. Viedt C, Orth SR. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it do more than simply attract monocytes? Nephrol Dial Transplant 17: 2043-2047, 2002. (Pubitemid 35446657)
38. Zager RA. Mitochondrial free radical production induces lipid peroxidation during myohemoglobinuria. Kidney Int 49: 741-751, 1996. (Pubitemid 26093083)
39. Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68: 1533-1542, 2005.
40. Zager RA. Uremia induces proximal tubular cytoresistance, and heme oxygenase-1 expression in the absence of acute kidney injury. Am J Physiol Renal Physiol 296: F362-F368, 2009.
41. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65: 2108-2112, 2004.
42. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms, and consequences. Kidney Int 66: 144-156, 2004.
43. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-α mRNA production, and TNF-α release. Am J Physiol Renal Physiol 288: F290-F297, 2005.
44. Zager RA, Johnson AC, Lund S. Uremia impacts renal inflammatory cytokine gene expression in the setting of experimental acute kidney injury. Am J Physiol Renal Physiol 297: F961-F970, 2009.
45. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis, and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002. (Pubitemid 34701216)